Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arbutus Biopharma ( (ABUS) ) has issued an announcement.
On May 7, 2025, Arbutus Biopharma presented data at the EASL Congress 2025, showcasing the potential of imdusiran, an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, in treating chronic hepatitis B (cHBV). The late-breaker poster highlighted that imdusiran, when combined with VTP-300 and low dose nivolumab, achieved a functional cure in some cHBV patients. The Phase 1a/1b trial of AB-101 demonstrated safety and high receptor occupancy without liver dysfunction. These findings suggest promising advancements in HBV treatment, potentially impacting Arbutus’s market position and offering hope for stakeholders in addressing the significant unmet medical need of cHBV.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
Arbutus Biopharma is currently facing substantial financial and operational challenges. The declining financial performance, coupled with technical indicators pointing to potential volatility and a negative valuation outlook, weigh heavily on the stock’s prospects. Additionally, recent executive changes and legal issues further contribute to the risk profile, resulting in a below-average stock score.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, specifically developing treatments for chronic hepatitis B virus (HBV) infection. The company is working on RNAi therapeutic imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101).
Average Trading Volume: 1,041,980
Technical Sentiment Signal: Buy
Current Market Cap: $635.7M
Learn more about ABUS stock on TipRanks’ Stock Analysis page.